CytoMed Therapeutics Ltd SEC Filings

CytoMed Therapeutics Limited furnished a Form 6-K noting it issued a press release on November 6, 2025. The update announces a non-dilutive investment for its subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd and provides updates on its new China strategy.

The press release is included as Exhibit 99.1 titled “CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy.”

CytoMed Therapeutics Limited reported that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his shareholding through recent open‑market purchases of 105,824 shares.

According to the accompanying press release title, his effective ownership is now 21.95%. The update was furnished on a Form 6‑K dated October 22, 2025.

CytoMed Therapeutics Limited reported that it has submitted a cash bid of an undisclosed sum for a potential acquisition of selected, potentially synergistic assets of TC BioPharm Limited. The announcement was made on October 14, 2025, and notes that TC BioPharm entered administration on October 2, 2025.

The update signals an interest in expanding CytoMed’s capabilities through asset acquisition, though terms and valuation were not disclosed. A related press release is furnished as Exhibit 99.1. As this is a bid for assets rather than a completed transaction, outcomes and financial effects depend on subsequent developments and any negotiated terms.

CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

CytoMed Therapeutics Limited (GDTC) prospectus supplement (Form 424B5) provides table-of-contents items and partial financial and capitalization data related to an offering and pro forma adjustments. The filing shows ordinary shares outstanding of 11,540,000 on an actual basis, 11,836,348 pro forma and 14,268,520 as adjusted (assuming 2,432,172 shares issued in the offering). Total liabilities are presented as 1,023,960 and 749,495 (two comparative figures). Accumulated losses are shown as (14,848,135) and (10,868,200) with pro forma accumulated losses of (16,224,695) and (11,875,783). Total capitalization appears as 10,067,749 and 7,369,162 with an as-adjusted capitalization of 15,587,229 and 11,409,185. Net tangible assets are reported as 8,950,739 and 6,551,558 and as-adjusted 14,470,219 and 10,591,581, with net tangible asset per share figures around $0.78, $0.57, and as-adjusted $1.01/$0.74. The supplement also includes Malaysian tax rate references (examples: 17%, 24%, royalties 10%, interest 15%, dividends exempt). Much of the provided text is a table of contents and fragmented table rows rather than full narrative disclosure.

CytoMed Therapeutics (GDTC) filed a Form 6-K to furnish a 21 Jul 2025 press release. The company has completed Dose Level 1 of its first-in-human Phase I dose-escalation “ANGELICA” trial of CTM-N2D, an investigational cell therapy for patients with advanced solid tumours or haematological malignancies, and has been cleared to begin Dose Level 2. The milestone indicates initial safety/tolerability at the starting dose, a prerequisite for further escalation and eventual efficacy assessment.

The filing contains no financial data, guidance, or corporate transactions; its sole purpose is to publicly disclose this clinical progress (Exhibit 99.1). Investors should view the news as an early-stage, non-pivotal signal of programme momentum rather than a determinant of near-term revenue.